A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years

NCT07536048 · tracked via the Priya Life Science Australia tracker

Sponsor

Sanofi Pasteur, a Sanofi Company

Phase

Observational

Started

2026-04-20

Last updated

2026-06-11

Condition(s) studied

Epstein-Barr Virus (EBV)Healthy Volunteers

Investigational drug(s) / intervention(s)

Investigational Procedure

Investigational Procedure: It consists of prospective blood and saliva collections. Study without any IMP administration.

Study summary

This multi-center, prospective, longitudinal cohort study is designed to gather immunological and clinical data on EBV reactivation in EBV seropositive adults aged 18 to 29 years.

This study will follow a cohort of approximately 100 EBV seropositive adults 18 to 29 years of age in Australia over a 6 or 12-month period.

Participants will not receive any study intervention (eg, study treatments, vaccines).

Eligibility

Sex

ALL

Min age

18 Years

Max age

29 Years

Healthy volunteers

Accepted

Inclusion Criteria: * Aged 18 to 29 years on the day of inclusion * Participants who are healthy as determined by medical evaluation including medical history and physical examination * Participants who are EBV seropositive based on serology testing Exclusion Criteria: Any condition which in the opinion of the investigator might interfere with the evaluation of the study objectives, including planning to leave the area of the study before the end of study period The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcome measure(s)

Number of participants with EBV DNA in blood and saliva at each study visit — 6 or 12 months
Serology testing indicative of EBV reactivation, measured by anti-VCA IgG/IgM, anti-EBNA-1 IgG and anti-EA IgG at each study visit — 6 or 12 months

Trial sites (2)

Facility	City	Region	Status
Griffith - University Clinical Trial Unit - Site Number : 0360001	Gold Coast	Australia
University of Sunshine Coast - Site Number : 0360002	South Brisbane	Australia

More Sanofi Pasteur, a Sanofi Company trials in Australia

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age Active, not recruiting

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne Recruiting

Other trials for the same condition

A Phase I Study to Evaluate LIFE-001 Recruiting

A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. Recruiting

A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults Recruiting

A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults Active, not recruiting

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ME3241 Administered Intravenously in Healthy Adult Participants Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07536048 on ClinicalTrials.gov ↗ ← All trials in Australia